Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has earned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $130.0769.

ABVX has been the subject of several recent analyst reports. Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $110.00 to $90.00 in a report on Tuesday, June 2nd. Barclays raised their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Citizens Jmp raised their price objective on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Wolfe Research set a $136.00 price objective on Abivax in a research note on Wednesday, June 3rd.

Institutional Trading of Abivax

Institutional investors and hedge funds have recently made changes to their positions in the stock. GHP Investment Advisors Inc. raised its position in shares of Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Abivax during the 4th quarter worth approximately $61,000. Finally, WPG Advisers LLC raised its position in shares of Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $96.55 on Friday. Abivax has a 1 year low of $5.69 and a 1 year high of $148.83. The firm has a market cap of $7.69 billion, a price-to-earnings ratio of -18.53 and a beta of 0.69. The stock’s 50-day simple moving average is $116.01 and its 200-day simple moving average is $119.12.

Abivax (NASDAQ:ABVX) last announced its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, research analysts predict that Abivax will post -3.4 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.